Know the latest price of dabrafenib now

Dabrafenib is an orally administered targeted therapy that belongs to the BRAF kinase inhibitor category. It is mainly used to treat certain types of cancer that carry mutations in the BRAF gene, especially malignant melanoma (melanoma) and non-small cell lung cancer. BRAF is a protein that plays an important role in cell signaling pathways, and mutations in the BRAF gene can lead to abnormal activation of the BRAF protein, thereby promoting the growth and spread of cancer cells.

Dabrafenib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. However, its price is relatively high, about 10,000 yuan. Please consult the local hospital pharmacy for specific prices. In contrast, the prices of dabrafenib generic drugs in foreign markets are relatively affordable, mainly Lao generic drugs, with prices of around two to three thousand yuan, which is far lower than domestic prices. It should be emphasized that there is no significant difference in the drug ingredients between these foreign generic drugs and domestic original drugs. Therefore, patients can flexibly choose the source of drugs according to their own economic status and actual needs.

Dabrafenib exerts its therapeutic effect by inhibiting the activity of BRAF protein. It binds to the activation site of BRAF protein and blocks the phosphorylation activity of BRAF protein, thus inhibiting the activation of downstream signaling pathways and preventing abnormal proliferation and growth of cancer cells.

Due to its targeting effect, dabrafenib can more precisely target tumors with specific BRAF mutations, making treatment more personalized and effective. Compared with traditional chemotherapy drugs, dabrafenib's targeting can also reduce the adverse effects on normal cells, thus reducing many treatment-related side effects.

However, it is important to note that dabrafenib is not suitable for all types of cancer. It mainly targets tumors carrying specific BRAF gene mutations. Therefore, before using dabrafenib, patients often undergo genetic testing to determine whether their tumors are suitable for treatment with the drug.